Experimental drug for advanced colorectal, esophageal, stomach, or ovarian cancer
Treatments studied
Part of Cancer clinical trials.
This study tests an experimental drug called IMC-R117C for people with certain advanced cancers. It aims to see if the drug can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific immune marker called HLA-A*02:01 (your doctor can check this with a blood test).
- You have advanced colorectal, esophageal, stomach, or ovarian cancer that has already been treated with standard therapies.
- You are able to do most daily activities on your own (ECOG 0 or 1).
- You do not have untreated or active cancer spread to the brain.
- You do not have a recent or ongoing bowel obstruction.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
This trial tests an experimental drug, IMC-P115C, for people with advanced cancers that have a specific marker called PRAME and a genetic type HLA-A*02:01. It may be an option if other treatments have stopped working or caused side effects.
This Phase 1 study tests TTX-080, a drug designed to block a cancer immune “signal” (HLA-G) to help the body fight advanced colorectal cancer. It mainly checks safety and how the treatment works in people with cancer that has spread.
This trial tests an experimental drug called IMC-001 for people whose cancer has spread or is locally advanced and has a high number of genetic mutations (TMB-H). The drug aims to help the immune system fight cancer.
This Phase 1 study tests IMC-002 in people with advanced cancers that did not respond to standard therapy. It may help by trying a new immune-targeting drug approach when other options have failed.
This trial tests a combination of radiation therapy, an immunotherapy drug (QL1706), and two targeted drugs (TAS-102 and bevacizumab) for people with advanced colorectal cancer that has spread and is not removable by surgery. It aims to see if this combination can help shrink tumors or slow cancer growth.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.